Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis.

about

Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis.

Item

http://www.wikidata.org/entity/Q36339246

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@ast

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@en

type

Item

label

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@ast

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@en

prefLabel

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@ast

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@en

P1476

Clinical efficacy of anti-VEGF ...... oretinopathy: a meta-analysis.

@en

P2093

Jiansu Chen

http://www.w3.org/2001/XMLSchema#string

Shangli Ji

http://www.w3.org/2001/XMLSchema#string

Shibo Tang

http://www.w3.org/2001/XMLSchema#string

Yemei Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Central Serous Chorioretinopathy Treatments: A Mini Review

Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy

Central serous chorioretinopathy: an update on pathogenesis and treatment.

The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.

Central serous chorioretinopathy: update on pathophysiology and treatment.

Choroidal thickness and choroidal blood flow after intravitreal bevacizumab injection in eyes with central serous chorioretinopathy.

The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.

Central serous chorioretinopathy: what we have learnt so far.

RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis.

Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy

P2888

s11096-017-0460-4

P304

514-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S11096-017-0460-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28386700

http://www.w3.org/2001/XMLSchema#string